title: Methysergide-induced valvular heart disease: a report of 2 cases.
abstract: Methysergide is a serotonin antagonist and is used as a long-term prophylactic treatment for migraine. Although many patients experience adequate control of migraine episodes, methysergide has been reported to cause retroperitoneal and pleuropulmonary fibrosis. Cardiovascular side effects mainly in the form of valvular fibrosis have been less recognized. We report 2 cases of methysergide-related mitral valve fibrosis.
authors.affiliation: Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia. alializzi@hotmail.com
authors.forename: Ali M
authors.initials: AM
authors.lastname: Alizzi
authors.forename: Ayman H
authors.initials: AH
authors.lastname: Al-Masri
authors.forename: Mark M
authors.initials: MM
authors.lastname: Murton
authors.forename: Anand S
authors.initials: AS
authors.lastname: Dixit
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Hemli
authors.forename: Michael
authors.initials: M
authors.lastname: Challis
authors.forename: Tuck
authors.initials: T
authors.lastname: Yong
authors.forename: Michael R
authors.initials: MR
authors.lastname: Nicholson
mesh_terms: D005260:Female; D005355:Fibrosis; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008784:Methysergide / Q000009:adverse effects*; D008875:Middle Aged; D008943:Mitral Valve / Q000473:pathology; D012702:Serotonin Antagonists / Q000009:adverse effects*
chemical_list: D012702:Serotonin Antagonists; D008784:Methysergide